127 related articles for article (PubMed ID: 10192939)
1. Three-dimensional quantitative structure-activity relationship (QSAR) and receptor mapping of cytochrome P-450(14 alpha DM) inhibiting azole antifungal agents.
Talele TT; Kulkarni VM
J Chem Inf Comput Sci; 1999; 39(2):204-10. PubMed ID: 10192939
[TBL] [Abstract][Full Text] [Related]
2. Docking analysis of a series of cytochrome P-450(14) alpha DM inhibiting azole antifungals.
Talele TT; Hariprasad V; Kulkarni VM
Drug Des Discov; 1998 May; 15(3):181-90. PubMed ID: 9689500
[TBL] [Abstract][Full Text] [Related]
3. Classical QSAR study on chromene derivatives as lanosterol 14alpha- demethylase inhibitor: a non azole antifungal target.
Vasanthanathan P; Lakshmi M; Babu MA; Kaskhedikar SG
Med Chem; 2006 Jul; 2(4):363-7. PubMed ID: 16848747
[TBL] [Abstract][Full Text] [Related]
4. Molecular modelling of lanosterol 14 alpha-demethylase (CYP51) from Saccharomyces cerevisiae via homology with CYP102, a unique bacterial cytochrome P450 isoform: quantitative structure-activity relationships (QSARs) within two related series of antifungal azole derivatives.
Lewis DF; Wiseman A; Tarbit MH
J Enzyme Inhib; 1999; 14(3):175-92. PubMed ID: 10445042
[TBL] [Abstract][Full Text] [Related]
5. A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals.
Ji H; Zhang W; Zhou Y; Zhang M; Zhu J; Song Y; Lü J
J Med Chem; 2000 Jun; 43(13):2493-505. PubMed ID: 10891108
[TBL] [Abstract][Full Text] [Related]
6. Sterol 14 alpha-demethylase and its inhibition: structural considerations on interaction of azole antifungal agents with lanosterol 14 alpha-demethylase (P-450(14DM)) of yeast.
Yoshida Y; Aoyama Y
Biochem Soc Trans; 1991 Aug; 19(3):778-82. PubMed ID: 1783215
[No Abstract] [Full Text] [Related]
7. Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.
Sheng C; Zhang W; Ji H; Zhang M; Song Y; Xu H; Zhu J; Miao Z; Jiang Q; Yao J; Zhou Y; Zhu J; Lü J
J Med Chem; 2006 Apr; 49(8):2512-25. PubMed ID: 16610794
[TBL] [Abstract][Full Text] [Related]
8. Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 alpha-sterol demethylase purified from Candida albicans.
Hitchcock CA; Dickinson K; Brown SB; Evans EG; Adams DJ
Biochem J; 1990 Mar; 266(2):475-80. PubMed ID: 2180400
[TBL] [Abstract][Full Text] [Related]
9. New azoles with potent antifungal activity: design, synthesis and molecular docking.
Che X; Sheng C; Wang W; Cao Y; Xu Y; Ji H; Dong G; Miao Z; Yao J; Zhang W
Eur J Med Chem; 2009 Oct; 44(10):4218-26. PubMed ID: 19539408
[TBL] [Abstract][Full Text] [Related]
10. Differential inhibition of Candida albicans CYP51 with azole antifungal stereoisomers.
Lamb DC; Kelly DE; Baldwin BC; Gozzo F; Boscott P; Richards WG; Kelly SL
FEMS Microbiol Lett; 1997 Apr; 149(1):25-30. PubMed ID: 9103974
[TBL] [Abstract][Full Text] [Related]
11. Structure-based rational design, synthesis and antifungal activity of oxime-containing azole derivatives.
Xu Y; Sheng C; Wang W; Che X; Cao Y; Dong G; Wang S; Ji H; Miao Z; Yao J; Zhang W
Bioorg Med Chem Lett; 2010 May; 20(9):2942-5. PubMed ID: 20362444
[TBL] [Abstract][Full Text] [Related]
12. Comparison of lanosterol-14 alpha-demethylase (CYP51) of human and Candida albicans for inhibition by different antifungal azoles.
Trösken ER; Adamska M; Arand M; Zarn JA; Patten C; Völkel W; Lutz WK
Toxicology; 2006 Nov; 228(1):24-32. PubMed ID: 16989930
[TBL] [Abstract][Full Text] [Related]
13. Inhibition by a novel azole antifungal agent with a geranyl group on lanosterol 14 alpha-demethylase of yeast.
Aoyama Y; Ishida K; Hori K; Sakaguchi A; Kudoh M; Yoshida Y
Biochem Pharmacol; 1992 Nov; 44(9):1701-5. PubMed ID: 1449529
[TBL] [Abstract][Full Text] [Related]
14. Modeling and interactions of Aspergillus fumigatus lanosterol 14-alpha demethylase 'A' with azole antifungals.
Gollapudy R; Ajmani S; Kulkarni SA
Bioorg Med Chem; 2004 Jun; 12(11):2937-50. PubMed ID: 15142553
[TBL] [Abstract][Full Text] [Related]
15. Differential inhibition of human CYP3A4 and Candida albicans CYP51 with azole antifungal agents.
Lamb DC; Kelly DE; Baldwin BC; Kelly SL
Chem Biol Interact; 2000 Mar; 125(3):165-75. PubMed ID: 10731517
[TBL] [Abstract][Full Text] [Related]
16. Improved model of lanosterol 14alpha-demethylase by ligand-supported homology modeling: validation by virtual screening and azole optimization.
Sheng C; Wang W; Che X; Dong G; Wang S; Ji H; Miao Z; Yao J; Zhang W
ChemMedChem; 2010 Mar; 5(3):390-7. PubMed ID: 20157915
[TBL] [Abstract][Full Text] [Related]
17. Molecular design of two sterol 14alpha-demethylase homology models and their interactions with the azole antifungals ketoconazole and bifonazole.
Rupp B; Raub S; Marian C; Höltje HD
J Comput Aided Mol Des; 2005 Mar; 19(3):149-63. PubMed ID: 16059669
[TBL] [Abstract][Full Text] [Related]
18. Antifungal Azoles: Structural Insights into Undesired Tight Binding to Cholesterol-Metabolizing CYP46A1.
Mast N; Zheng W; Stout CD; Pikuleva IA
Mol Pharmacol; 2013 Jul; 84(1):86-94. PubMed ID: 23604141
[TBL] [Abstract][Full Text] [Related]
19. Novel insights into P450 BM3 interactions with FDA-approved antifungal azole drugs.
Jeffreys LN; Poddar H; Golovanova M; Levy CW; Girvan HM; McLean KJ; Voice MW; Leys D; Munro AW
Sci Rep; 2019 Feb; 9(1):1577. PubMed ID: 30733479
[TBL] [Abstract][Full Text] [Related]
20. Effects of Y132H and F145L substitutions on the activity, azole resistance and spectral properties of Candida albicans sterol 14-demethylase P450 (CYP51): a live example showing the selection of altered P450 through interaction with environmental compounds.
Kudo M; Ohi M; Aoyama Y; Nitahara Y; Chung SK; Yoshida Y
J Biochem; 2005 May; 137(5):625-32. PubMed ID: 15944416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
